Lerochol is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

The pivotal phase 3 RINGSIDE trial investigated varegacestat, an oral gamma secretase inhibitor, in patients with progressing desmoid tumors.

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

Tolebrutinib is currently being reviewed by the Food and Drug Administration (FDA) for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS). A regulatory decision on the ...

Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil.

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Gepotidacin is an oral triazaacenaphthylene bacterial type II topoisomerase inhibitor approved based on data from the phase 3 EAGLE-1 study.

The FDA approval of berotralstat oral pellets offers a new prophylaxis option for children aged 2 years and older with hereditary angioedema.

The phase 3 MINT study evaluated inebilizumab, a CD-19 directed cytolytic antibody, in 238 patients with gMG, including those who were anti-AChR-Ab+ and anti-MuSK-Ab+.

ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy ...

HealthDay News — Federal officials say the US Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and children following COVID-19 vaccination. Federal officials say ...

HealthDay News — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi ...